SOP Der herzkranke Diabetespatient

Evidenz aus klinischen Studien der vergangenen Jahre hat zu wesentlichen Veränderungen der Therapieempfehlungen für Patienten mit Diabetes mellitus mit begleitenden kardiovaskulären Risikofaktoren und Erkrankungen geführt. Im nachfolgenden Diagnostik- und Therapiealgorithmus werden aktuelle Empfehlungen unterschiedlicher Leitlinien in einem vereinfachten, pragmatischen Leitfaden kombiniert, der auf den weit überwiegenden Teil aller Patienten mit Typ-2-Diabetes angewendet werden kann.

Schlüsselwörter

Diabetes mellitus - koronare Herzkrankheit - Herzinsuffizienz - kardiovaskuläre Risikofaktoren

Publication History

Article published online:
28 March 2022

• Literatur

• 1 Sinclair A, Saeedi P, Kaundal A. et al. Diabetes and global ageing among 65–99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2020; 162: 108078 DOI: 10.1016/j.diabres.2020.108078. (PMID: 32068097)
• 2 Pearson-Stuttard J, Bennett J, Cheng YJ. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 2021; 9: 165-173 DOI: 10.1016/s2213-8587(20)30431-9. (PMID: 33549162)
• 3 Visseren FLJ, Mach F, Smulders YM. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021; 42: 3227-3337 DOI: 10.1093/eurheartj/ehab484. (PMID: 34458905)
• 4 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128 DOI: 10.1056/NEJMoa1504720. (PMID: 26378978)
• 5 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380: 347-357 DOI: 10.1056/NEJMoa1812389. (PMID: 30415602)
• 6 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657 DOI: 10.1056/NEJMoa1611925. (PMID: 28605608)
• 7 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322 DOI: 10.1056/NEJMoa1603827. (PMID: 27295427)
• 8 Marso SP, Bain SC, Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844 DOI: 10.1056/NEJMoa1607141. (PMID: 27633186)
• 9 Hernandez AF, Green JB, Janmohamed S. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392: 1519-1529 DOI: 10.1016/s0140-6736(18)32261-x. (PMID: 30291013)
• 10 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130 DOI: 10.1016/s0140-6736(19)31149-3. (PMID: 31189511)
• 11 Cosentino F, Grant PJ, Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2019; 41: 255-323 DOI: 10.1093/eurheartj/ehz486. (PMID: 31497854)
• 12 Buse JB, Wexler DJ, Tsapas A. et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63: 221-228 DOI: 10.1007/s00125-019-05039-w. (PMID: 31853556)
• 13 Brown E, Heerspink HJL, Cuthbertson DJ. et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 2021; 398: 262-276 DOI: 10.1016/s0140-6736(21)00536-5. (PMID: 34216571)
• 14 Bakris GL, Fonseca V, Katholi RE. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236 DOI: 10.1001/jama.292.18.2227. (PMID: 15536109)
• 15 Ray KK, Bays HE, Catapano AL. et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med 2019; 380: 1022-1032 DOI: 10.1056/NEJMoa1803917. (PMID: 30865796)
• 16 Ray KK, Wright RS, Kallend D. et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 2020; 382: 1507-1519 DOI: 10.1056/NEJMoa1912387. (PMID: 32187462)
• 17 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-1424 DOI: 10.1056/NEJMoa2022190. (PMID: 32865377)
• 18 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008 DOI: 10.1056/NEJMoa1911303. (PMID: 31535829)
• 19 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021; 42: 3599-3726 DOI: 10.1093/eurheartj/ehab368. (PMID: 34447992)
• 20 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385: 1451-1461 DOI: 10.1056/NEJMoa2107038. (PMID: 34449189)